Cuenta de resultados
MADRIGAL PHARMACEUTICALS, INC.
MDGL
Resumen del rendimiento
Haga clic en cualquier fila de la tabla para añadirla al gráfico
en millones de USD
| Métrica | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ingresos
|
958.40 | 180.13 | 0.00 | - | 0.00 | 0.00 | - | - | - | - | - | 0.00 | - | - | - |
|
Coste de los ingresos
|
- | 6.23 | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Beneficio bruto
|
958.40 | 173.90 | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Gastos operativos
|
1,258.50 | 435.06 | 380.50 | 293.57 | 242.48 | 206.67 | 94.97 | 40.68 | 32.06 | 25.22 | 67.61 | 83.95 | 87.56 | 61.09 | 53.02 |
|
Investigación y desarrollo
|
388.53 | 236.72 | 272.35 | 245.44 | 205.16 | 184.81 | 72.32 | 25.39 | 24.39 | 15.93 | 54.22 | 68.21 | 71.86 | 49.41 | 41.46 |
|
Ventas, generales y administrativos
|
813.83 | 435.06 | 108.15 | 48.13 | 37.32 | 21.86 | 22.65 | 15.29 | 7.67 | 9.29 | 13.39 | 15.75 | 15.70 | 11.68 | 11.55 |
|
Otros gastos operativos
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Resultado de explotación
|
-300.10 | -261.16 | -380.50 | -293.57 | -242.48 | -206.67 | -94.97 | -40.68 | -32.06 | -25.22 | -67.61 | -83.95 | -87.56 | -61.09 | -53.02 |
|
Ingresos no operativos
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Ingresos por intereses
|
37.36 | 46.65 | 19.58 | 2.19 | 0.36 | 4.33 | 11.02 | 7.67 | 0.56 | 0.05 | - | - | - | - | - |
|
Gastos por intereses
|
- | - | 12.71 | 3.96 | - | - | - | - | - | 1.21 | 1.10 | 2.10 | 2.50 | 1.40 | - |
|
Otros ingresos/gastos no operativos
|
-0.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Resultado antes de impuestos
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Gasto por impuesto sobre beneficios
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Participaciones no dominantes
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Beneficio neto
|
-288.28 | -465.89 | -373.63 | -295.35 | -241.85 | -202.24 | -83.95 | -32.81 | - | - | - | - | - | - | - |
Información complementaria
Datos por acción, partidas derivadas y otras – no forman parte de la cuenta de resultados
en millones de USD, salvo que se indique lo contrario
| Métrica | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciación y amortización
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-298.59 | -260.06 | -379.97 | -293.10 | -242.08 | -206.20 | -94.86 | -40.59 | -31.99 | -25.22 | -66.95 | -83.28 | -87.04 | -60.35 | -51.55 |
|
Beneficio por acción (básico)
|
-12.85 | -21.90 | -19.99 | -17.23 | - | - | - | - | - | - | - | - | - | - | -1.00 |
|
BPA diluido
|
-12.85 | -21.90 | -19.99 | -17.23 | - | - | - | - | - | - | - | - | - | - | -1.00 |
|
Promedio ponderado de acciones
|
22.43 | 21.27 | 18.69 | 17.14 | - | - | - | - | - | - | - | - | - | - | 47.20 |
|
Promedio ponderado diluido de acciones
|
22.43 | 21.27 | 18.69 | 17.14 | - | - | - | - | - | - | - | - | - | - | 47.20 |
|
Resultado global
|
-287.88 | -465.89 | -373.13 | -295.30 | -241.97 | -202.41 | -83.41 | -33.10 | -31.21 | -26.36 | -68.67 | -86.17 | -90.18 | -62.79 | -47.37 |